Differential mutagenicity of aflatoxin B1 in the liver of neonatal and adult mice

Environmental and Molecular Mutagenesis

Volumn 51, Issue 2, 2010, Pages 156-163

  Chen, Tao ^a   Heflich, Robert H ^a   Moore, Martha M ^a   Mei, Nan ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Aflatoxin B1; Glutathione S transferase; Mutagenicity; Mutation; Neonate

Indexed keywords

AFLATOXIN B1; DNA; GLUTATHIONE TRANSFERASE;

AGEISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DNA ADDUCT; GENE CONVERSION; GENE FREQUENCY; LIVER; LIVER TUMOR; MALE; MOUSE; MUTAGENICITY; MUTATION RATE; NEWBORN; NONHUMAN; TRANSGENIC MOUSE;

AFLATOXIN B1; AGING; ANIMALS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; GENOME; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MUTAGENICITY TESTS; POINT MUTATION; POISONS; TRANSCRIPTION FACTORS; VIRAL PROTEINS;

MUS; MUS MUSCULUS;

EID: 77249177182     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20518     Document Type: Article

References (37)

1. Adams WT, Skopek TR. 1987. Statistical test for the comparison of samples from mutational spectra. J Mol Biol 194:391-396.
2. Autrup H, Jorgensen EC, Jensen O. 1996. Aflatoxin B1 induced lacI mutation in liver and kidney of transgenic mice C57BL/6N: Effect of phorone. Mutagen 11:69-73.
3. Bailey EA, Iyer RS, Stone MP, Harris TM, Essigmann JM. 1996. Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci USA 93:1535-1539.
4. Banuett F, Hoyt MA, McFarlane L, Echols H, Herskowitz I. 1986. hflB, a new Escherichia coli locus regulating lysogeny and the level of bacteriophage lambda cII protein. J Mol Biol 187:213-224.
5. Bedard LL, Alessi M, Davey S, Massey TE. 2005. Susceptibility to aflatoxin B1-induced carcinogenesis correlates with tissue-specific differences in DNA repair activity in mouse and in rat. Cancer Res 65:1265-1270.
6. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431.
7. Chen T, Gamboa da Costa G, Marques MM, Shelton SD, Beland FA, Manjanatha MG. 2002. Mutations induced by alpha-hydroxytamoxifen in the lacI and cII genes of Big Blue transgenic rats. Carcinogenesis 23:1751-1757.
8. Chen T, Mittelstaedt RA, Beland FA, Heflich RH, Moore MM, Parsons BL. 2005. 4-Aminobiphenyl induces liver DNA adducts in both neonatal and adult mice but induces liver mutations only in neonatal mice. Int J Cancer 117:182-187.
9. Croy RG, Wogan GN. 1981a. Quantitative comparison of covalent aflatoxin-DNA adducts formed in rat and mouse livers and kidneys. J Natl Cancer Inst 66:761-768.
10. Croy RG, Wogan GN. 1981b. Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer Res 41:197-203.
11. Croy RG, Essigmann JM, Reinhold VN, Wogan GN. 1978. Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proc Natl Acad Sci USA 75:1745-1749.
12. Dycaico MJ, Stuart GR, Tobal GM, de Boer JG, Glickman BW, Provost GS. 1996. Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacI transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis 17:2347-2356.
13. Eaton D,Van Ness K,Beutler T, editors. 1993. GST Mediated Protection Against Carcinogens: Aflatoxin B1 as an Example. Boca Raton: CRC Press. pp 187-198.
14. Essigmann JM, Croy RG, Nadzan AM, Busby WF Jr, Reinhold VN, Buchi G, Wogan GN. 1977. Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. Proc Natl Acad Sci USA 74:1870-1874.
15. Essigmann JM, Green CL, Croy RG, Fowler KW, Buchi GH, Wogan GN. 1983. Interactions of aflatoxin B1 and alkylating agents with DNA: Structural and functional studies. Cold Spring Harb Symp Quant Biol 47 (Part 1):327-337.
16. Flammang TJ, Tungeln LS, Kadlubar FF, Fu PP. 1997. Neonatal mouse assay for tumorigenicity: Alternative to the chronic rodent bioassay. Regul Toxicol Pharmacol 26:230-240.
17. Foster PL, Eisenstadt E, Miller JH. 1983. Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci USA 80:2695-2698.
18. Gorrod JW, Carter RL, Roe FJ. 1968. Induction of hepatomas by 4-aminobiphenyl and three of its hydroxylated derivatives administered to newborn mice. J Natl Cancer Inst 41:403-410.
19. Groopman JD, Croy RG, Wogan GN. 1981. In vitro reactions of aflatoxin B1-adducted DNA. Proc Natl Acad Sci USA 78:5445-5449.
20. Hengstler JG, Van der Burg B, Steinberg P, Oesch F. 1999. Interspecies differences in cancer susceptibility and toxicity. Drug Metab Rev 31:917-970.
21. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428.
22. IARC. 1990. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Pharmaceutical Drugs. Lyon: IARC. pp 123-141.
23. IARC. 1993. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Naturally Occurring Substances: Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. Lyon: IARC. pp 197-572.
24. Jakubczak JL, Merlino G, French JE, Muller WJ, Paul B, Adhya S, Garges S. 1996. Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Proc Natl Acad Sci USA 93:9073-9078.
25. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. 2006. Cancer statistics, 2006. CA Cancer J Clin 56:106-130.
26. Kohler SW, Provost GS, Kretz PL, Fieck A, Sorge JA, Short JM. 1990. The use of transgenic mice for short-term, in vivo mutagenicity testing. Genet Anal Tech Appl 7:212-218.
27. Li D, Cao Y, He L, Wang NJ, Gu JR. 1993. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 14:169-173.
28. Lin JK, Miller JA, Miller EC. 1977. 2,3-Dihydro-2-(guan-7-yl)-3-hydroxy- aflatoxin B1, a major acid hydrolysis product of aflatoxin B1-DNA or -ribosomal RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in vivo. Cancer Res 37:4430-4438.
29. Martin CN, Garner RC. 1977. Aflatoxin B-oxide generated by chemical or enzymic oxidation of aflatoxin B1 causes guanine substitution in nucleic acids. Nature 267:863-865.
30. Mei N, Heflich RH, Moore MM, Chen T. 2005. Age-dependent sensitivity of Big Blue transgenic mice to the mutagenicity of N-ethyl-N-nitrosourea (ENU) in liver. Mutat Res 572:14-26.
31. Miller EC. 1978. Some current perspectives on chemical carcinogenesis in humans and experimental animals: Presidential Address. Cancer Res 38:1479-1496.
32. Shupe T, Sell S. 2004. Low hepatic glutathione S-transferase and increased hepatic DNA adduction contribute to increased tumorigenicity of aflatoxin B1 in newborn and partially hepatectomized mice. Toxicol Lett 148:1-9.
33. Slikker W III, Mei N, Chen T. 2004. N-ethyl-N-nitrosourea (ENU) increased brain mutations in prenatal and neonatal mice but not in the adults. Toxicol Sci 81:112-120.
34. Swenson DH, Lin JK, Miller EC, Miller JA. 1977. Aflatoxin B1-2,3-oxide as a probable intermediate in the covalent binding of aflatoxins B1 and B2 to rat liver DNA, ribosomal RNA in vivo. Cancer Res 37:172-181.
35. Thybaud V, Dean S, Nohmi T, de Boer J, Douglas GR, Glickman BW, Gorelick NJ, Heddle JA, Heflich RH, Lambert I, Martus H-J, Mirsalis JC, Suzuki T, Yajima N. 2003. In vivo transgenic mutation assays. Mutat Res 540:141-151.
36. Vesselinovitch SD, Mihailovich N, Wogan GN, Lombard LS, Rao KV. 1972. Aflatoxin B 1, a hepatocarcinogen in the infant mouse. Cancer Res 32:2289-2291.
37. Wogan GN. 1969. Metabolism and biochemical effects of aflatoxins. In: Goldblatt LA, editor. Aflatoxin-Scientific Background Control and Implications. New York: Wiley. pp 321-350.